Return to Today's science sparks archives

2017-07-03

Fig 1. Distribution of patient-reported health care service use by each toxicity and corresponding severity rating.

Fig 1. Distribution of patient-reported health care service use by each toxicity and corresponding severity rating.
  • Friese CR, Harrison JM, Janz NK, Jagsi R, Morrow M, Li Y, Hamilton AS, Ward KC, Kurian AW, Katz SJ, Hofer TP

  • Cancer. 2017 Jun 1;123(11):1925-1934.

2017-07-05

Fig 1. Structure of the human DPF2 tandem PHD finger domain.

Fig 1. Structure of the human DPF2 tandem PHD finger domain.
  • Huber FM, Greenblatt SM, Davenport AM, Martinez C, Xu Y, Vu LP, Nimer SD, Hoelz A

  • Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):6016-6021.

2017-07-06

Fig 3. Orthotopically transplanted organoids progress to metastatic CRC.

Fig 3. Orthotopically transplanted organoids progress to metastatic CRC.
  • O'Rourke KP, Loizou E, Livshits G, Schatoff EM, Baslan T, Manchado E, Simon J, Romesser PB, Leach B, Han T, Pauli C

  • Nat Biotechnol. 2017 Jun;35(6):577-582.

2017-07-10

Fig 1. Visual framework for treatment decision making in older adults with cancer.

Fig 1. Visual framework for treatment decision making in older adults with cancer.
  • Maggiore R, Zumsteg ZS, BrintzenhofeSzoc K, Trevino KM, Gajra A, Korc-Grodzicki B, Epstein JB, Bond SM, Parker I, Kish JA, Murphy BA

  • Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):868-883.

2017-07-11

Fig 1. Transient IFNγ Drives Persistent T Cell Activation Caused by Upregulation of Antigen Processing and Presentation.

Fig 1. Transient IFNγ Drives Persistent T Cell Activation Caused by Upregulation of Antigen Processing and Presentation.
  • Oyler-Yaniv J, Oyler-Yaniv A, Shakiba M, Min NK, Chen YH, Cheng SY, Krichevsky O, Altan-Bonnet N, Altan-Bonnet G

  • Mol Cell. 2017 Jun 1;66(5):635-647.e7.

2017-07-12

Fig 4. Negative-stain electron microscopy of yeast MCM in the absence and presence of Cdt1.

Fig 4. Negative-stain electron microscopy of yeast MCM in the absence and presence of Cdt1.
  • Frigola J, He J, Kinkelin K, Pye VE, Renault L, Douglas ME, Remus D, Cherepanov P, Costa A, Diffley JFX

  • Nat Commun. 2017 Jun 23;8:15720.
Open Access button

2017-07-13

Fig 1. A small molecule clears pathogens from the gut.

Fig 1. A small molecule clears pathogens from the gut.
  • Jung HJ, Pamer EG

  • Nature. 2017 Jun 22;546(7659):479-480.

2017-07-14

Fig 3. Change in baseline in HRQoL for patient response and AEs subgroups.

Fig 3. Change in baseline in HRQoL for patient response and AEs subgroups.
  • Schadendorf D, Larkin J, Wolchok J, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao C, Wagstaff J

  • Eur J Cancer. 2017 Jun 22;82:80-91.
Open Access button

2017-07-17

Fig 4. SFK/FAK pathway inhibition most potently enhances the effects of osimertinib.

Fig 4. SFK/FAK pathway inhibition most potently enhances the effects of osimertinib.
  • Ichihara E, Westover D, Meador CB, Yan Y, Bauer JA, Lu P, Ye F, Kulick A, De Stanchina E, McEwen R, Ladanyi M

  • Cancer Res. 2017 Jun 1;77(11):2990-3000.

2017-07-19

Fig 1. Impact of NRP1-Deficient Tregs on WT Tregs.

Fig 1. Impact of NRP1-Deficient Tregs on WT Tregs.
  • Merghoub T, Wolchok JD

  • Cell. 2017 Jun 1;169(6):981-982.

2017-07-21

Fig 1. Schematic shows architecture of radiologist-technologist feedback system.

Fig 1. Schematic shows architecture of radiologist-technologist feedback system.
  • Ong L, Elnajjar P, Nyman CG, Mair T, Juluru K

  • AJR Am J Roentgenol. 2017 Jul;209(1):W18-W25.

2017-07-24

Fig 1. Diagram illustrating the known factors contributing to the development of antibiotic resistance in Clostridium difficile.

Fig 1. Diagram illustrating the known factors contributing to the development of antibiotic resistance in Clostridium difficile.
  • Peng Z, Jin D, Kim HB, Stratton CW, Wu B, Tang YW, Sun X

  • J Clin Microbiol. 2017 Jul;55(7):1998-2008.

2017-07-25

Fig 2. PD-1 is also expressed on T-cells following TCR engagement and activation.

Fig 2. PD-1 is also expressed on T-cells following TCR engagement and activation.
  • Park JA, Cheung NV

  • Cancer Treat Rev. 2017 Jun 1;58:22-33.

2017-07-26

Fig 1. Sagittal images of 4 representative patients.

Fig 1. Sagittal images of 4 representative patients.
  • Grkovski M, Schöder H, Lee NY, Carlin SD, Beattie BJ, Riaz N, Leeman JE, O'Donoghue JA, Humm JL

  • J Nucl Med. 2017 Jul;58(7):1072-1080.

2017-07-27

Fig 1. Microscopic pictures of an ATC in association with a PTC, tall cell variant (PTC-TCV) in a 5.5-cm lateral neck lymph node of a 68-year-old male patient.

Fig 1. Microscopic pictures of an ATC in association with a PTC, tall cell variant (PTC-TCV) in a 5.5-cm lateral neck lymph node of a 68-year-old male patient.
  • Xu B, Scognamiglio T, Cohen PR, Prasad ML, Hasanovic A, Michael Tuttle R, Katabi N, Ghossein RA

  • Hum Pathol. 2017 May 25. pii: S0046-8177(17)30170-3.

2017-07-28

Fig 3. Distribution of programmed death-ligand 1 expression scores and response to pembrolizumab across all cohorts.

Fig 3. Distribution of programmed death-ligand 1 expression scores and response to pembrolizumab across all cohorts.
  • Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A

  • J Clin Oncol. 2017 Jul 1;35(19):2125-2132.

2017-07-31

Fig 6. An axial, coronal, and sagittal snapshot of the In-phase MRI, deformed planning CT and synthetic CT generated using our proposed approach for patient #10.

Fig 6. An axial, coronal, and sagittal snapshot of the In-phase MRI, deformed planning CT and synthetic CT generated using our proposed approach for patient #10.
  • Farjam R1, Tyagi N1, Veeraraghavan H1, Apte A1, Zakian K1, Hunt MA1, Deasy JO

  • Med Phys. 2017 Jul;44(7):3706-3717.

2017-08-01

Fig 1. Schematic representation of contacts between TopN and a segment of the 24-mer DNA duplex containing the 5′-CCCTT-3′ consensus sequence (spDNA).

Fig 1. Schematic representation of contacts between TopN and a segment of the 24-mer DNA duplex containing the 5′-CCCTT-3′ consensus sequence (spDNA).
  • Reed B, Yakovleva L, Shuman S, Ghose R

  • Biochemistry. 2017 Jul 5;56(26):3307-3317.

2017-08-02

Fig 1. Etv1CreERT2 temporally activates cre in the Etv1-expressing ICC subclasses.

Fig 1. Etv1CreERT2 temporally activates cre in the Etv1-expressing ICC subclasses.
  • Ran L, Murphy D, Sher J, Cao Z, Wang S, Walczak E, Guan Y, Xie Y, Shukla S, Zhan Y, Antonescu CR, Chen Y, Chi P

  • Cancer Res. 2017 Jul 15;77(14):3758-3765.

2017-08-03

Fig 1. The neurologic, oncologic, mechanicals stability and systemic disease framework.

Fig 1. The neurologic, oncologic, mechanicals stability and systemic disease framework.
  • Barzilai O, Laufer I, Yamada Y, Higginson DS, Schmitt AM, Lis E, Bilsky MH

  • J Clin Oncol. 2017 Jul 20;35(21):2419-2427.

2017-08-04

Fig 3. FOXA1 mutations act through E2F and increase tolerance to anti-oestrogen receptor treatment.

Fig 3. FOXA1 mutations act through E2F and increase tolerance to anti-oestrogen receptor treatment.
  • Rheinbay E, Parasuraman P, Grimsby J, Tiao G, Engreitz JM, Kim J, Lawrence MS, Taylor-Weiner A, Rodriguez-Cuevas S, Rosenberg M, Hess J, Stewart C, Maruvka YE, Stojanov P, Cortes ML, Seepo S, Cibulskis C, Tracy A, Pugh TJ, Lee J, Zheng Z, Ellisen LW, Iafrate AJ, Boehm JS, Gabriel SB, Meyerson M, Golub TR, Baselga J, Hidalgo-Miranda A, Shioda T, Bernards A, Lander ES, Getz G.

  • Nature. 2017 Jul 6;547(7661):55-60.

2017-08-07

Fig 3. PCNSL is highly chemosensitive.

Fig 3. PCNSL is highly chemosensitive.
  • Grommes C, DeAngelis LM

  • J Clin Oncol. 2017 Jul 20;35(21):2410-2418.

2017-08-08

Fig 2. Model of multistage MDR development driven by perturbations in sphingomyelin, glucosylceramide and ABCB1.

Fig 2. Model of multistage MDR development driven by perturbations in sphingomyelin, glucosylceramide and ABCB1.
  • Lee WK, Kolesnick RN

  • Cell Signal. 2017 Jul 4;38:134-145.

2017-08-09

Fig 1. Chelator-free radiolabeling of SERRS nanoparticles.

Fig 1. Chelator-free radiolabeling of SERRS nanoparticles.
  • Wall MA, Shaffer TM, Harmsen S, Tschaharganeh DF, Huang CH, Lowe SW, Drain CM, Kircher MF

  • Theranostics 2017; 7(12):3068-3077.
Open Access button

2017-08-10

Fig 4. Visual monitoring of SERRS nanoparticle synthesis.

Fig 4. Visual monitoring of SERRS nanoparticle synthesis.
  • Harmsen S, Wall MA, Huang R, Kircher MF

  • Nat Protoc. 2017 Jul;12(7):1400-1414.

2017-08-11

Fig 1. Treatment response in the 16 pembrolizumab-treated patients with rrPMBCL who were evaluable (by imaging) for efficacy at the time of data cutoff.

Fig 1. Treatment response in the 16 pembrolizumab-treated patients with rrPMBCL who were evaluable (by imaging) for efficacy at the time of data cutoff.
  • Zinzani PL, Ribrag V, Moskowitz CH, Michot JM, Kuruvilla J, Balakumaran A, Zhang Y, Chlosta S, Shipp MA, Armand P

  • Blood. 2017 Jul 20;130(3):267-270.

2017-08-14

Fig 1. Glucose Starvation Induces Entosis in Breast Cancer Cell Lines

Fig 1. Glucose Starvation Induces Entosis in Breast Cancer Cell Lines
  • Hamann JC, Surcel A, Chen R, Teragawa C, Albeck JG, Robinson DN, Overholtzer M

  • Cell Rep. 2017 Jul 5;20(1):201-210.
Open Access button

2017-08-15

Fig 4. Long-term rapamycin treatment slows down tumor growth in GIST-T1 and induces tumor arrest in JJ012 and CS1 in vivo.

Fig 4. Long-term rapamycin treatment slows down tumor growth in GIST-T1 and induces tumor arrest in JJ012 and CS1 in vivo.
  • Di Gialleonardo V, Aldeborgh HN, Miloushev V, Folkers KM, Granlund K, Tap WD, Lewis JS, Weber WA, Keshari KR

  • Cancer Res. 2017 Jun 1;77(11):3113-3120.

2017-08-16

Fig 1. Antitumor response and durability of dalantercept.

Fig 1. Antitumor response and durability of dalantercept.
  • Voss MH, Bhatt RS, Plimack ER, Rini BI, Alter RS, Beck JT, Wilson D, Zhang X, Mutyaba M, Glasser C, Attie KM, Sherman ML, Pandya SS, Atkins MB

  • Clin Cancer Res. 2017 Jul 15;23(14):3557-3565.

2017-08-17

Fig 8. Percentage of interferon-γ (IFN-γ) expressing cells among CD56bright and CD56dim natural killer cells from patients and controls, upon in vitro stimulation with IL-12 and IL-18. Bars represent mean ± SD values.

Fig 8. Percentage of interferon-γ (IFN-γ) expressing cells among CD56bright and CD56dim natural killer cells from patients and controls, upon in vitro stimulation with IL-12 and IL-18. Bars represent mean ± SD values.
  • Dobbs K, Tabellini G, Calzoni E, Patrizi O, Martinez P, Giliani SC, Moratto D, Al-Herz W, Cancrini C, Cowan M, Bleesing J

  • Front Immunol. 2017 Jul 17;8:798.
Open Access button

2017-08-18

Fig 1. Levels of the Pc Mark H3K27me3 as a Function of Polymerase at Genes and Genome Wide.

Fig 1. Levels of the Pc Mark H3K27me3 as a Function of Polymerase at Genes and Genome Wide.
  • Berrozpe G, Bryant GO, Warpinski K, Spagna D, Narayan S, Shah S, Ptashne M

  • Cell Rep. 2017 Jul 25;20(4):785-793.
Open Access button

2017-08-21

Fig 5. Pathway analysis in uterine adenosarcomas and phyllodes tumors of the breast.

Fig 5. Pathway analysis in uterine adenosarcomas and phyllodes tumors of the breast.
  • Geyer FC, Burke KA, Piscuoglio S, Ng CK, Papanastasiou AD, Marchiò C, Selenica P, Edelweiss M, Murray MP, Brogi E, Soslow RA

  • Mol Oncol. 2017 Aug;11(8):913-926.
Open Access button

2017-08-22

Fig 1. Patient survival and clinical response to pembrolizumab across 12 different tumor types with mismatch repair deficiency.

Fig 1. Patient survival and clinical response to pembrolizumab across 12 different tumor types with mismatch repair deficiency.
  • Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F

  • Science. 2017 Jul 28;357(6349):409-413.

2017-08-24

Fig 5. P-Rspo3 tumours are molecularly distinct from Apc-mutant tumours.

Fig 5. P-Rspo3 tumours are molecularly distinct from Apc-mutant tumours.
  • Han T, Schatoff EM, Murphy C, Zafra MP, Wilkinson JE, Elemento O, Dow LE

  • Nat Commun. 2017 Jul 11;8:15945.
Open Access button

2017-08-25

Fig 1. Spatial and temporal heterogeneity in primary and metastatic lesions in treatment-naïve synchronous metastatic breast cancer.

Fig 1. Spatial and temporal heterogeneity in primary and metastatic lesions in treatment-naïve synchronous metastatic breast cancer.
  • Ng CK, Bidard FC, Piscuoglio S, Geyer FC, Lim RS, De Bruijn I, Shen R, Pareja F, Berman SH, Wang L, Pierga JY

  • Clin Cancer Res. 2017 Aug 1;23(15):4402-4415.

2017-08-28

Fig 1. Mechanisms of action of commonly used systemic agents in treatment of renal cell carcinoma (RCC).

Fig 1. Mechanisms of action of commonly used systemic agents in treatment of renal cell carcinoma (RCC).
  • Shingarev R, Jaimes EA

  • Am J Physiol Renal Physiol. 2017 Aug 1;313(2):F145-F154.

2017-08-29

Fig 1. The predicted binding mode of RXDX-105 with RET.

Fig 1. The predicted binding mode of RXDX-105 with RET.
  • Li GG, Somwar R, Joseph J, Smith RS, Hayashi T, Martin L, Franovic A, Schairer A, Martin E, Riely GJ, Harris J

  • Clin Cancer Res. 2017 Jun 15;23(12):2981-2990.

2017-08-30

Fig 3. A, Role of MRD in timing of HDT therapy in multiple myeloma schema 1. B, Role of MRD in post-HDT consolidation schema 2. C, Role of MRD in maintenance therapy in multiple myeloma schema 3. D, Role of MRD in duration of therapy in non-transplant setting schema 4.

Fig 3. A, Role of MRD in timing of HDT therapy in multiple myeloma schema 1. B, Role of MRD in post-HDT consolidation schema 2. C, Role of MRD in maintenance therapy in multiple myeloma schema 3. D, Role of MRD in duration of therapy in non-transplant setting schema 4.
  • Anderson KC, Auclair D, Kelloff GJ, Sigman CC, Avet-Loiseau H, Farrell AT, Gormley NJ, Kumar SK, Landgren O, Munshi NC, Cavo M

  • Clin Cancer Res. 2017 Aug 1;23(15):3980-3993.

2017-08-31

Fig 1. Representative dose distributions of PRT versus Intensity Modulated Radiation Therapy (XRT).

Fig 1. Representative dose distributions of PRT versus Intensity Modulated Radiation Therapy (XRT).
  • Boimel PJ, Berman AT, Li J, Apisarnthanarax S, Both S, Lelionis K, Larson GL, Teitelbaum U, Lukens JN, Ben-Josef E, Metz JM

  • Journal of Gastrointestinal Oncology. 2017 Mar 22. 8(4):665-674.
Open Access button

2017-09-05

Fig 1. Key Questions Remain.

Fig 1. Key Questions Remain.
  • Hellmann MD, Snyder A

  • Immunity. 2017 Aug 15;47(2):221-223.

2017-09-06

Fig 1. Plot of estimated glomerular filtration rate (eGFR) over time for 130 metastatic renal cell carcinoma patients starting at first administration of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI), stratified by baseline eGFR.

Fig 1. Plot of estimated glomerular filtration rate (eGFR) over time for 130 metastatic renal cell carcinoma patients starting at first administration of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI), stratified by baseline eGFR.
  • Boursiquot BC, Zabor EC, Glezerman IG, Jaimes EA

  • Hypertension. 2017 Sep 1;70(3):552-8.

2017-09-07

Fig 1. A and B, Mutation map showing the location of mutations in NRAS (A) and KRAS (B).

Fig 1. A and B, Mutation map showing the location of mutations in NRAS (A) and KRAS (B).
  • Cercek A, Braghiroli MI, Chou JF, Hechtman JF, Kemeny NE, Saltz L, Capanu M, Yaeger R

  • Clin Cancer Res. 2017 Aug 15;23(16):4753-4760.

2017-09-08

Fig 1: ZSCAN10 preserves genomic stability in iPSCs through the maintenance of ROS levels.

Fig 1: ZSCAN10 preserves genomic stability in iPSCs through the maintenance of ROS levels.
  • Bárcena C, López-Otín C

  • Nat Cell Biol. 2017 Aug 31;19(9):1012-1013.

2017-09-11

Fig 3.Imbalance of ROS–glutathione homeostasis in mouse A-iPSCs, and recovery by ZSCAN10 expression via reduction of GSS.

Fig 3.Imbalance of ROS–glutathione homeostasis in mouse A-iPSCs, and recovery by ZSCAN10 expression via reduction of GSS.
  • Skamagki M, Correia C, Yeung P, Baslan T, Beck S, Zhang C, Ross CA, Dang L, Liu Z, Giunta S, Chang TP

  • Nat Cell Biol. 2017 Sep;19(9):1037-1048.

2017-09-12

Fig 4. Transcription Factor Binding Displayed as Ordered Heatmaps at Specific Sites.

Fig 4. Transcription Factor Binding Displayed as Ordered Heatmaps at Specific Sites.
  • Narayan S, Bryant G, Shah S, Berrozpe G, Ptashne M

  • Cell Rep. 2017 Aug 15;20(7):1585-1596.
Open Access button

2017-09-13

Fig 1. MF, hematoxylin-eosin stain.

Fig 1. MF, hematoxylin-eosin stain.
  • Pulitzer M

  • Clin Lab Med. 2017 Sep;37(3):527-546.

2017-09-14

Fig 1. Schematic of the TEC-Seq method.

Fig 1. Schematic of the TEC-Seq method.
  • Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, Anagnostou V, Fiksel J, Cristiano S, Papp E, Speir S

  • Sci Transl Med. 2017 Aug 16;9(403).

2017-09-15

Fig 2. Heatmap of p-values of pairwise association analysis of co-stimulatory and co-inhibitory immune checkpoint molecules and TILs.

Fig 2. Heatmap of p-values of pairwise association analysis of co-stimulatory and co-inhibitory immune checkpoint molecules and TILs.
  • Arbour KC, Naidoo J, Steele KE, Ni A, Moreira AL, Rekhtman N, Robbins PB, Karakunnel J, Rimner A, Huang J, Riely GJ

  • PLoS One. 2017; 12(8): e0182665.
Open Access button

2017-09-18

Fig 1. CBL mutations and currently published mouse models of mutant Cbl.

Fig 1. CBL mutations and currently published mouse models of mutant Cbl.
  • Lee SC, Abdel-Wahab O

  • Blood. 2017 Apr 13;129(15):2046-2048.

2017-09-19

Fig 3. Diverse classes of gene fusions identified in metastatic cancers.

Fig 3. Diverse classes of gene fusions identified in metastatic cancers.
  • Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, Cao X, Rabban E, Kumar-Sinha C, Raymond V, Schuetze S

  • Nature. 2017 Aug 17;548(7667):297-303.

2017-09-20

Fig 1. 3D Organotypic Glioma Invasion Model. Patient-derived glioblastoma (GBM) cells are engineered to express GFP and seeded onto a mouse brain slice.

Fig 1. 3D Organotypic Glioma Invasion Model. Patient-derived glioblastoma (GBM) cells are engineered to express GFP and seeded onto a mouse brain slice.
  • Codega P, Mellinghoff IK

  • Trends Mol Med. 2017 Sep;23(9):776-777.

2017-09-21

Fig 6. Deletion of Aid leads to transcriptional alteration of some key regulators of erythropoiesis and enhanced DNA methylation in gene regulatory elements.

Fig 6. Deletion of Aid leads to transcriptional alteration of some key regulators of erythropoiesis and enhanced DNA methylation in gene regulatory elements.
  • Kunimoto H, McKenney AS, Meydan C, Shank K, Nazir A, Rapaport F, Durham B, Garrett-Bakelman FE, Pronier E, Shih AH, Melnick A

  • Blood. 2017 Mar 30;129(13):1779-1790.
Open Access button

2017-09-22

Fig 6. Targeting glycosylation-dependent MUC16 function.

Fig 6. Targeting glycosylation-dependent MUC16 function.
  • Rao TD, Fernández-Tejada A, Axelrod A, Rosales N, Yan X, Thapi S, Wang A, Park KJ, Nemieboka B, Xiang J, Lewis JS

  • ACS Chem Biol. 2017 Aug 18;12(8):2085-2096.

2017-09-25

Fig 1. Schematic description of the mathematical model of a kinase cascade.

Fig 1. Schematic description of the mathematical model of a kinase cascade.
  • Luo M

  • Biochemistry. 2017 Aug 29;56(34):4443-4444.

2017-09-26

Fig 1. The intestinal microbiota mediates colonization resistance against pathogens by both direct and indirect mechanisms of action.

Fig 1. The intestinal microbiota mediates colonization resistance against pathogens by both direct and indirect mechanisms of action.
  • Kim S, Covington A, Pamer EG

  • Immunol Rev. 2017 Sep;279(1):90-105.

2017-09-27

Fig 5. Pmel-1 T cells are located near to and interact with Tregs in YFP-B16 tumors.

Fig 5. Pmel-1 T cells are located near to and interact with Tregs in YFP-B16 tumors.
  • Budhu S, Schaer DA, Li Y, Toledo-Crow R, Panageas K, Yang X, Zhong H, Houghton AN, Silverstein SC, Merghoub T, Wolchok JD

  • Sci. Signal.. 2017 Aug 29;10(494):eaak9702.

2017-09-28

Fig 1. Males from the ENU-induced mutant line rahu display meiotic defects.

Fig 1. Males from the ENU-induced mutant line rahu display meiotic defects.
  • Jain D, Meydan C, Lange J, Claeys Bouuaert C, Lailler N, Mason CE, Anderson KV, Keeney S

  • PLoS Genet. 2017 Aug 30;13(8):e1006964.
Open Access button

2017-09-29

Fig 1. Single-cell sequencing for the decomposition of heterogeneous cellular populations and the analysis of rare cells in lung cancer.

Fig 1. Single-cell sequencing for the decomposition of heterogeneous cellular populations and the analysis of rare cells in lung cancer.
  • Baslan T, Hicks J

  • Nat Rev Cancer. 2017 Aug 24;17(9):557-569.